Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

Inclusion Criteria

• •At least 15 years of age Except: where local regulations and/or institutional policies do not allow for subjects \< 18 years of age (pediatric population) to participate. For those sites, the eligible subject population is ≥ 18 years of age
• •Completely removed melanoma by surgery performed within 12 weeks of randomization
• •Stage IIIb/C or Stage IV before complete resection
• •No previous anti-cancer treatment